Earn 1.5 CE Credits

Click below to register.

Tuesday, September 24, 2019

Philadelphia Marriott Downtown

Philadelphia, PA

Room: Salon C–D – 5th Floor

Registration and Lunch 11:00 AM – 11:30 AM
Interactive CE Symposium 11:30 AM – 1:00 PM

This educational activity is supported by an educational grant from GlaxoSmithKline.

This event is not part of the official AAFP FMX.

Management of chronic obstructive pulmonary disease (COPD), a complex, heterogeneous disease, has been complicated by new recommendations that incorporate novel escalation strategies with dual long-acting ß agonist (LABA)/long-acting muscarinic antagonist (LAMA) bronchodilation treatments and LAMA/LABA/inhaled corticosteroid (ICS) triple therapy. Dual bronchodilation and triple therapy treatment options are both now available as fixed-dose combination (FDC) inhalers. However, despite these updated recommendations and new inhaler options, limited practical guidance on individualizing therapy or identifying patients who may benefit from treatment escalation exists. In addition, lack of knowledge of appropriate COPD inhaler choice/use and self-management strategies persists, precluding optimal therapeutic benefit and clinical outcomes. This live, interactive activity will feature 2 experts in COPD, who will review and discuss advances in dual bronchodilation and triple drug inhalation therapy, the most recent COPD recommendations, as well as implementation of practical individualized treatment and inhaler strategies for patients with COPD.

The goal of this CE activity is for physicians, physician assistants, nurse practitioners, and nurses who manage patients with COPD in primary care settings to improve their knowledge base on COPD management strategies and related clinical guidelines and to translate this knowledge into optimizing individualized COPD treatment plans in practice.

This educational initiative is designed for primary care physicians, physician assistants, nurse practitioners, and nurses who manage patients with COPD.

After participating in this activity, participants will demonstrate an improved ability to:
  • DESCRIBE the most up-to-date scientific evidence supporting the use of inhaled maintenance therapies, including dual bronchodilation and ICS-containing regimens, for COPD.
  • EXPLAIN initial and escalation therapy recommendations for inhaled maintenance therapy based on the most recent COPD guidelines.
  • RECOGNIZE the symptoms and patient burden of COPD exacerbations, and the resulting need to escalate therapy.
  • SELECT appropriate initial and escalation inhaled maintenance treatment strategies based on patient symptoms, exacerbation risks, inhaler device, and clinical guidelines.
  • PROPOSE strategies that provide disease education and inhaler training to patients with COPD.
accme_logoIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and ASiM CE LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education – The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education – The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.

Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.

Application for CME credit has been filed with the American Academy of Family Physicians. Determination of credit is pending.

11:00 – 11:30 AM Activity Registration and Lunch
11:30 – 11:40 AM Program Overview
11:40 AM – 12:00 PM Addressing Unmet Needs of COPD Patients: One Size Does Not Fit All
Stephen A. Brunton, MD
12:00 – 12:20 PM Remaining Up-to-Date with COPD Treatment Guidelines and Pharmacotherapy Options – Case-Based Presentation
Barbara P. Yawn, MD, MSc, FAAFP
12:20 – 12:30 PM The Importance of the Inhaler: Improving Outcomes with Device Selection and Education
Stephen A. Brunton, MD
12:30 – 12:45 PM Individualizing Therapy for COPD
Barbara P. Yawn, MD, MSc, FAAFP and Stephen A. Brunton, MD
12:45 – 12:55 PM Q&A
12:55 – 1:00 PM Conclusions and Postassessment

This schedule is subject to change.

Barbara P. Yawn, MD, MSc, FAAFP (Chair)
Adjunct Professor
Department of Family and Community Health University of Minnesota
Minneapolis, Minnesota
Chief Science Officer of the COPD Foundation
Miami, Florida

Stephen A. Brunton, MD
Executive Director
Primary Care Respiratory Group
Murrieta, California

Featuring Patient Faculty Member John Linnell
State Captain, COPD Foundation

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Americans with Disabilities Act (ADA)
Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact Adrienne Roser prior to the live event at 908-253-9001 ext. 23.

There is no fee for this educational activity.

Submit a case to review at meeting:

<img src="" alt="procced to pretest" border="0" />

MyCMESite is published by ASiM CE, LLC, d/b/a ASiM 166 W. Main Street, Somerville, NJ 08876. (908) 253-9001. Copyright ©2017 by ASiM CE, LLC. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from the publisher. ASiM is a registered trademark of ASiM CE LLC. Contact Us